The Coverage Gap: Managing Conflicting Payer Policies in Molecular Testing

Protect lab reimbursement and compliance with strategies to reduce claim denials.

Molecular and genetic testing continue to advance at a rapid pace, but payer policies rarely move as quickly. For laboratory billing executives and managers, this creates a familiar challenge: navigating overlapping, conflicting, and constantly evolving coverage rules across Medicare, commercial payers, and laboratory benefit managers (LBMs).

During a recent webinar with Lighthouse Lab Services, we explored where payer policies overlap, where they collide, and how lab leaders can navigate those challenges while protecting reimbursement and staying compliant.

Why Payer Conflicts Are Increasing

As utilization of molecular diagnostics grows, so does scrutiny from payers. Increased spend, expanded test menus, and a rise in laboratory-developed tests (LDTs) have accelerated payers’ efforts to define, refine, and enforce coverage criteria.

Key drivers include:

• Rising Medicare and commercial payer spend on molecular testing
• Rapid innovation outpacing formal coverage policies
• Heightened focus on fraud, waste, and abuse
• Expanded use of front-end utilization controls

The result is a complex policy landscape where assumptions—such as “Medicare sets the standard”—can create downstream risk.

Understanding the Policy Landscape

Laboratories are often managing multiple, sometimes conflicting policies at once:

• Medicare LCDs & NCDs
  Local and national coverage determinations set criteria for traditional Medicare, often varying by Medicare Administrative Contractor (MAC).
• Commercial Payer Policies
  Commercial plans may reference Medicare guidance—or ignore it entirely—developing their own medical necessity criteria, documentation rules, and coding requirements.
• Laboratory Benefit Managers (LBMs)
  Organizations like Carelon and EviCore influence utilization management through prior authorizations, policy development, and claims review.
• MolDX Program
  Widely adopted for molecular diagnostics, MolDX introduces Z‑codes, technical assessments, and standardized test identification. While not universal yet, adoption continues to expand across MACs and commercial plans.

Where Conflicts Create Risk

Misalignment across these frameworks can have serious consequences for your lab. Increased denials and downcoding chip away at revenue, while post-payment audits and recoupments create financial exposure after the fact. Pre-payment medical record reviews slow cash flow and add friction to the billing process, and the cumulative effect of all three drives up administrative burden across your team.

One of the most important takeaways from the webinar: the absence of a clear policy today is not the same as protection. As utilization grows, payer scrutiny follows—and labs already billing at scale are often the first to come under review. Staying ahead of that curve means treating policy silence as a signal to prepare, not a reason to stand down.

Future Predictions

Practical Strategies to Reduce Denials

While policy complexity is unavoidable, labs can take proactive steps to stabilize revenue:

• Stay current on payer policy updates, MAC bulletins, and coverage changes
• Monitor denial trends and remark codes to identify patterns early
• Align documentation closely with medical necessity requirements
• Use assigned Z‑codes consistently once established
• Conduct internal audits to identify high‑risk tests and claims

Some organizations are also exploring technology and AI to help monitor policy changes, flag high‑risk claims, and improve clean-claim rates.

The Bottom Line

Payer policies are evolving to catch up with molecular testing innovation—and that evolution often brings tighter guardrails. For billing leaders, success depends on understanding not just individual policies, but how they intersect and influence one another. The more visibility you have into payer intent, coverage criteria, and policy direction, the better positioned your lab will be to avoid denials and protect long‑term revenue.

Watch the On‑Demand Webinar

Ready to take a more strategic approach to payer policy in your lab? Watch the on-demand webinar to go deeper on payer conflicts, MolDX adoption, LBM influence, and revenue cycle strategies you can put into practice right away. Presenters Ann Lambrix (Lighthouse Lab Services) and Tara Cepull offer a clearer path to operationalizing compliance across your billing operation.

Payer Conflicts and Guidelines:
Harmonizing LCDs, MolDx, & Commercial Plans

 And if you missed Episode 1 of the series, catch up here.